AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05085314 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional microscope
Description: Cataract surgery under topical anesthesia with a conventional microscope
Study NCT05118854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given by IV
Study NCT05427279 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participant will consume a supplemental dose of a placebo (20g maltodextrin with 50mg vitamin C)
Study NCT05427279 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolized Collagen
Description: The participant will consume a supplemental dose of Hydrolized collagen (20g with 50mg vitamin C)
Study NCT05427279 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PrimaColl
Description: The participant will consume a supplemental dose of PrimaColl, a vegan collagen supplementation (20g with 50mg vitamin C)
Study NCT05427279 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: The participant will consume a supplemental dose of whey protein (20g whey isolate with 50mg vitamin C)
Study NCT06173778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide 2.4mg
Description: Semaglutide 2.4mg will be self-administered once a week under the surface of the skin and will be started at 0.24mg once a week for 4 weeks; in 4-week intervals, the dose will be increased until a dose of 2.4mg is reached
Study NCT06173778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active medication, self-administered
Study NCT06173778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT, nicotine patch)
Description: Participants who smoke >10 cigarettes/day will use 21 mg patches for the first 6 weeks, 14 mg patches during weeks 7 and 8, and 7 mg patches during weeks 9 and 10. Participants who smoke 5-10 cigarettes per day will use 14 mg patches for the first 6 weeks and 7 mg patches for weeks 7-10.
Study NCT06173778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT, nicotine patch)
Description: Participants who smoke >10 cigarettes/day will use 21 mg patches for the first 6 weeks, 14 mg patches during weeks 7 and 8, and 7 mg patches during weeks 9 and 10. Participants who smoke 5-10 cigarettes per day will use 14 mg patches for the first 6 weeks and 7 mg patches for weeks 7-10.
Study NCT06173778 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief Smoking Cessation Counseling
Description: Participants will receive weekly, manual-based individual smoking cessation counseling. Counseling will be provided by master's level clinicians.
Study NCT05307263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combination therapy of atherectomy and DCB
Description: The target lesion in femoropopliteal artery will be treated with atherectomy folloewd by DCB. The choice of atherectomy devices (HawkOne, Jectstream, or Rotarex)and DCBs (IN.PACT or Ranger) will be left to the operator's decision. In presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of bare nitinol stents is recommended. Implantational of drug-eluting stents is not allowed.
Study NCT05307263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DCB alone
Description: The target lesion in femoropopliteal artery will be treated with DCB. The choice of DCBs (IN.PACT or Ranger) will be left to the operator's decision. In presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of bare nitinol stents is recommended. Implantational of drug-eluting stents is not allowed.
Study NCT06544993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meso-botox
Description: Micro-Botox, is a highly diluted Botulinum toxin type A
Study NCT04497610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breath sample
Description: Patient will blow into a tube 5 times.
Study NCT06173778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Smoking Cessation Counseling
Description: Participants will receive weekly, manual-based individual smoking cessation counseling. Counseling will be provided by master's level clinicians.
Study NCT05699759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K8
Description: Subjects will have the treatment administered intravitreally (one eye only) using an injector system on a 24-gauge needle to deliver a cylindrical, 3 mm long, drug eluting pellet containing 300 µg of K8. Participants will be followed for 168 days (24 weeks).
Study NCT06305351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-757 and K-833 QD
Description: Both administered orally once daily
Study NCT06305351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-757 and K-833 BID
Description: Both administered orally twice daily
Study NCT06305351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to K-757 and K-833 QD
Description: Both administered orally once daily
Study NCT06305351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to K-757 and K-833 BID
Description: Both administered orally twice daily
Study NCT06348355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]savolitinib
Description: Radiopharmaceutical; IMP; Sterile solution for IV injection, not more than 10 μg, single administration
Study NCT06348355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: IMP; 300 mg tablet, oral single administration
Study NCT06204263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: finger feeding
Description: The fathers of premature babies in intensive care will be interviewed and an educational booklet will be prepared about finger feeding, cleaning, hygiene, hand washing, the importance of sucking, and the rules to be followed to prevent infection in the newborn, and how to apply it will be explained by the researcher. Babies will be breastfed three times a day for seven days.
Study NCT05333068 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI revascularization strategy based on combined FFR and OCT assessment
Description: PCI revascularization strategy based on combined FFR and OCT assessment All FFR ≤ 0.75 and Vulnerable plaque will be treated. VP defined as TCFA ( cap thickness ≤ 75 micron); Ruptured plaque; or Plaque erosion with > 70 % AS or MLA \< 2.5 mm2.
Study NCT05333068 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: PCI revascularization strategy based FFR assessment
Description: PCI revascularization strategy based FFR assessment (all lesions with FFR≤0.80 will be treated)
Study NCT05998187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra-rectal botulinum toxin injections
Description: Patients with fecal incontinence who have failed conservative treatments and are candidates for intra-rectal botulinum toxin injections.
Study NCT05216978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology Intervention
Description: Weekly phone calls with the study interventionist and positive psychology exercises over an 9-week period. The positive psychology program exercises include three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
Study NCT06385574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality therapy
Description: Conventional hand therapy
Study NCT05684991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KMS-66 Ashwagandha 300mg
Description: One capsule is taken by mouth twice daily with water
Study NCT05684991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: One capsule is taken by mouth twice daily with water
Study NCT06286774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, \& Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
Study NCT06577324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live group music therapy
Description: The intervention will involve the use of live music in a group of patients during their quimiotherapy session. The intervention will last approximately forty minutes and will be organized into three stages: Opening (10 min), Body Awareness and Movement (7-10 minutes), Intervention Development (20 minutes). Genres and songs are performed based on the group's preferences and suggestions. The instruments used for the group intervention are the same as those mentioned earlier; participants are provided with percussion instruments, accompanied by the music therapist's voice and the participants' voices. The intervention encourages active participation, with users playing the instruments, singing, engaging in dialogue, and/or reflecting between songs.
Study NCT05936060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INMUNOCEM
Description: Mesenchymal Stromal Cell suspension intraarticularly injected
Study NCT05936060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO COMPARATOR
Description: Administration of plasmalyte as a vehicle for MSC
Study NCT03735277 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPC, Cord Blood
Description: HPC, Cord Blood is supplied as a cryopreserved cell suspension in a sealed bag containing a minimum of 5 × 10\^8 total nucleated cells with a minimum of 1.25 × 10\^6 viable CD34+ cells in a volume of 25 milliliters. The exact precryopreservation nucleated cell content is provided on the container label and accompanying records.
Study NCT06369363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be assigned to 1 week of transdermal placebo patch.
Study NCT06369363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Subjects will be assigned to 1 week of transdermal estradiol (0.05 mg/day) patch.
Study NCT05780125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FibCLOT
Description: 30 mg/kg of FibCLOT (rounded up to the nearest 2 or 3 grams) after protamine administration
Study NCT05780125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RiaSTAP
Description: 30 mg/kg of RiaSTAP (rounded up to the nearest 2 or 3 grams) after protamine administration
Study NCT06292741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sudoscan
Description: recording of sudomotor function and pupillary reactivity
Study NCT05576012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SOL-116
Description: Participants will receive SC injection in a double-blind manner
Study NCT05576012 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive SC injection in a double-blind manner
Study NCT05301361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Oral Solution
Description: The XRMPH or matching placebo will be started at a dose of 0.3 mg/kg/day and individually titrated over two weeks. Phone calls at the end of weeks 1, 2, and 3 will be used to collect adverse event and response data. If there is no evidence of side effects and ongoing symptoms of ADHD, the dose will be increased to 0.5 mg/kg/day at one week and 0.7 mg/kg/day at 2 weeks (maximum dose of 60 mg per day consistent with FDA labeled use in youth).
Study NCT05301361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate Oral Solution
Description: The XRMPH or matching placebo will be started at a dose of 0.3 mg/kg/day and individually titrated over two weeks. Phone calls at the end of weeks 1, 2, and 3 will be used to collect adverse event and response data. If there is no evidence of side effects and ongoing symptoms of ADHD, the dose will be increased to 0.5 mg/kg/day at one week and 0.7 mg/kg/day at 2 weeks (maximum dose of 60 mg per day consistent with FDA labeled use in youth).
Study NCT04757961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifeStories
Description: The content of LifeStories is divided thematically into core ACT concepts across the four episodes as follows: 1) cultivating awareness of the transient nature of mood experiences and the benefit of trying out various strategies to cope with depression when it arises; 2) clarifying one's own values and setting personal goals related to these values; 3) developing a more accepting and nonjudgmental stance towards difficult thoughts and feelings and practicing self-compassion;and 4) living more mindfully in the present moment.
Study NCT06402916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry drink
Description: Blueberry drink equivalent to 240g fresh blueberries.
Study NCT06402916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Drink containing no active ingredient.
Study NCT04693650 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroBlock UHF stimulation
Description: NeuroBlock ultrahigh frequency (UHF) stimulation with 500kHz intra-pulse
Study NCT06034002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA033989
Description: INCA033989 will be administered at protocol defined dose.
Study NCT05593016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)
Description: Participating in the SMILE arm of the study will consist of four, 60-minute sessions delivered over 6-8 weeks to patients in their homes using videoconferencing.~Intervention will provide training in behavioral symptom management skills (e.g.,relaxation training, activity-rest cycling) and include skills from ACT and MCP targeting avoidance of uncomfortable experiences (e.g., thoughts, emotions) and promoting engagement in value-directed activity.
Study NCT05593016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Control Arm
Description: The control arm will receive the NCI booklet, Taking Time: Support for People with Cancer, which provides basic strategies for symptom (e.g., pain, fatigue, stress) management, coping with negative emotions, and communication and will continue their usual medical care of advanced cancer.
Study NCT05252572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLL1 CAR T-cells
Description: Drug: CLL1 CAR T-cells Each subject receive CLL1 CAR T-cells by intravenous infusion Other Name: CLL1 CAR T-cells injection
Study NCT04744649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX or SOX
Description: XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S1 S-1: 40\~60mg Bid，d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA~JS001: 240mg, ivdrip, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40\~60mg Bid,d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA
Study NCT04744649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001+XELOX or SOX
Description: XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~JS001: 240mg, ivdrip, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40\~60mg Bid,d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA
Study NCT04744649 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: JS001+XELOX or SOX
Description: XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~JS001: 240mg, ivdrip, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40\~60mg Bid,d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA
Study NCT06313606 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fat positive control
Description: Dietary fat-containing meal plan with a specific supplement that may modify fat metabolism
Study NCT05527535 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diabetic retinopathy screening by artificial intelligence
Description: Screening diabetic patients' eyes with AI through digital health platform
Study NCT05527535 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diabetic retinopathy screening by healthcare personnel
Description: Screening diabetic patients' eyes by conventional method (healthcare personnel)
Study NCT06234839 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri (DSM 17938 and ATCC PTA 5289) in form of oral tablets
Description: Each subject of the experimental group was instructed to dissolve inside the mouth two tablets per day (in the morning and before going to bed at night), during the experimental period of 30 days. The tablets were provided by BioGaia ProDentis® (Stockholm, Sweden). The tablets contained two strains of L. reuteri (DSM-17938 and ATCC PTA 5289), at a dose of 2 x 108 CFU/tablet.
Study NCT05487001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dexamethasone group
Description: 1) Arm l (dexamethasone group) Ultrasound-guided femoral nerve block with 1% lidocaine 15 ml after the end of surgery Postoperative femoral nerve patient controlled analgesia~* Total volume 250 ml (0.375% ropivacaine 60 ml + normal saline 188 ml + dexamethasone 10 mg (2 ml))~* Basal rate 4 mL/hr, Bolus volume 2 mL, Lock-out time 15 min
Study NCT05487001 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham group
Description: 2) Arm ll (sham group) Ultrasound-guided femoral nerve block with 1% lidocaine 15 ml after the end of surgery Postoperative femoral nerve patient controlled analgesia~* Total volume 250 ml (0.375% ropivacaine 60 ml + normal saline 190 ml~* Basal rate 4 mL/hr, Bolus volume 2 mL, Lock-out time 15 min
Study NCT04904497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Occupational Therapy
Description: Occupational therapists will implement the following activities:~* Polysensory stimulation: external stimulation for increasing the level of alertness. It will be implemented with SAS 2 one session each 24 h.~* Cognitive stimulation: bundle of exercises for activating mental functions, i.e: alertness, visual perception, memory, calculus, problem solving, praxis, language. Patients with SAS 3, 4 and 5. In SAS \<2, 6> environmental orientation will be considered~* Basic activities of daily living (BADLs): promotion of independence that initially practice hygiene, personal grooming. Patients with SAS 3, 4 and 5~* Motor function Stimulation: exercises to keep the patient's upper extremities active and functional. Patients with SAS with 3,4 and 5. Patients with SAS 1 and 2 will use adaptations to prevent edema and bedsores on vulnerable body areas~* Education: trained family members and health staff about the intervention process
Study NCT06577740 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Otago Exercise
Description: Group-based otago exercises were performed for 4 weeks. They were also given a brochure containing otago exercises twice a week and applied individually and followed remotely. They were asked to walk normally for 30 minutes twice a week. They then entered a 4-week washout period.
Study NCT06577740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual Task Focused Otago Exercise
Description: After a 4-week washout period, face-to-face group-based and dual-task focused otago exercises were applied once a week for 4 weeks. Participants were given a brochure containing otago exercises including dual-task exercises twice a week and applied individually and monitored remotely. They were asked to walk normally for 30 minutes twice a week.
Study NCT05243797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered via a subcutaneous injection (SC)
Study NCT05243797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally
Study NCT05243797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally
Study NCT05776875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab Injection
Description: Atezolizumab is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), hepatocellular carcinoma, and alveolar soft part sarcoma It is a fully humanized, engineered monoclonal antibody of Immunoglobulin G1 (IgG1) isotype against the protein programmed cell death-ligand 1 (PD-L1).